Regeneron Pharmaceuticals Inc. buy Citigroup Inc.
Summary
This prediction is currently active. The BUY prediction by Citigroup_Inc_ currently has a performance of 21.16%. A total of €0.88 was paid as dividends for this prediction. This prediction currently runs until 29.10.26. The prediction end date can be changed by Citigroup_Inc_ at any time. Citigroup_Inc_ has 50% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Performance without dividends (%)
| Name | 1w |
|---|---|
| Regeneron Pharmaceuticals Inc. | 8.682% |
| iShares Core DAX® | 1.614% |
| iShares Nasdaq 100 | 2.191% |
| iShares Nikkei 225® | -0.459% |
| iShares S&P 500 | 2.385% |
Comments by Citigroup_Inc_ for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren
Stopped prediction by Citigroup_Inc_ for Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals Inc.
13.10.25
13.10.26
25.11.25
Regeneron Pharmaceuticals Inc.
02.06.25
02.06.26
25.11.25
Regeneron Pharmaceuticals Inc.
14.05.25
14.05.26
25.11.25

